Major R&D Pipeline: 3ADCs

(occurring in ≥20% of patients DS-3201 Ph1: Most Common TEAEs Most Common TEAEs All Histologies (N=77) PTCL (N=44) with TCL)b All grades Grade ≥3 All grades Grade ≥3 All grades ATL (N=14) Grade ≥3 Platelet count decreasedd 47 (61.0) 13 (16.9) 21 (47.7) 5 (11.4) 9 (64.3) 3 (21.4) Dysgeusia 40 (51.9) 0 20 (45.5) 0 8 (57.1) 0 Anemia 31 (40.3) 9 (11.7) 15 (34.1) 6 (13.6) 5 (35.7) 1 (7.1) Neutrophil count decreased 27 (35.1) 18 (23.4) 13 (29.5) 8 (18.2) 6 (42.9) 5 (35.7) Alopecia 26 (33.8) 0 12 (27.3) 0 6 (42.9) 0 WBC count decreased 23 (29.9) 12 (15.6) 10 (22.7) 6 (13.6) 4 (28.6) 3 (21.4) Diarrhea 22 (28.6) 1 (1.3) 13 (29.5) 0 3 (21.4) 0 Lymphocyte count decreased 22 (28.6) 17 (22.1) 7 (15.9) 6 (13.6) 2 (14.3) 2 (14.3) ALT increased 16 (20.8) 1 (1.3) 7 (15.9) 0 3 (21.4) Nausea 16 (20.8) 0 11 (25.0) 0 3 (21.4) 1 (7.1) 0 Daiichi-Sankyo ALT alanine aminotransferase; BCL, B-cell lymphoma; CTCAE, Common Terminology Criteria for Adverse Events; TEAE, treatment emergent adverse events; WBC, white blood cell. a Study sites could choose to enter thrombocytopenia or platelet count decreased as a term. b In order of frequency reported for patients with TCL (n=58). c Including 19 patients with BCLs. d Grade 3 platelet count decreased, CTCAE 5.0 definition: <50,000-25,000/mm3; <50.0-25.0 x 109/L. Demonstrated acceptable safety profile by appropriate monitoring and management of adverse events Grade ≥3 platelet count decreasea, and thrombocytopenia occurred in 13 patients (16.9%) and 2 patients (2.6%), respectively ➤ The median time to platelet count reduction to ≤50x109/L from the first dose was 15 days, and the median time to platelet count recovery to ≥50x109/L was 12 days 6 patients (9.8%) experienced dose interruption or reduction due to platelet count decrease/thrombocytopenia, but no patients discontinued treatment due to platelet count decrease/thrombocytopenia 25

View entire presentation